Prospective identification of potential factors influencing stem cell mobilization and the necessity for plerixafor use in newly diagnosed multiple myeloma patients undergoing autologous stem cell transplantation

Introduction: To study the efficacy and safety of single large volume leukapheresis by using generic G-CSF or G-CSF plus Plerixafor in achieving adequate stem cell yield and various factors influencing thereof in newly diagnosed multiple myeloma patients undergoing autologous stem cell transplant ....

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Gopal Krushna Ray, Rabindra Kumar Jena, Tribikram Panda, Sudha Sethy
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	GCSF Large volume leukapheresis (LVL) Plerixafor Stem cell yield Diseases of the blood and blood-forming organs RC633-647.5
Acceso en línea:	https://doaj.org/article/a95b46c4541f464eb7de7b52a9705552
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a95b46c4541f464eb7de7b52a9705552
record_format	dspace
spelling	oai:doaj.org-article:a95b46c4541f464eb7de7b52a97055522021-11-04T04:36:53ZProspective identification of potential factors influencing stem cell mobilization and the necessity for plerixafor use in newly diagnosed multiple myeloma patients undergoing autologous stem cell transplantation2531-137910.1016/j.htct.2020.04.011https://doaj.org/article/a95b46c4541f464eb7de7b52a97055522021-10-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2531137920300973https://doaj.org/toc/2531-1379Introduction: To study the efficacy and safety of single large volume leukapheresis by using generic G-CSF or G-CSF plus Plerixafor in achieving adequate stem cell yield and various factors influencing thereof in newly diagnosed multiple myeloma patients undergoing autologous stem cell transplant . Method: This prospective study was undertaken among 55 newly diagnosed multiple myeloma patients undergoing autologous stem cell transplant and aged between 18 and 75 years. Mobilization and harvesting of stem cells were performed by using GCSF or GCSF plus Plerixafor and large volume leukapheresis, respectively. A stem cell yield of ≥2 × 106 kg–1 and the number of apheresis procedures were primary efficacy endpoints, while the ideal stem cells yield >5 × 106 kg–1, the engraftment day and D100 response/graft sustainability were secondary endpoints. Result: The primary endpoint was achieved in all cases in both the groups by using a single LVL leukapheresis procedure. Fulfillment of all the secondary endpoints was satisfactory and comparable in both the groups. Age, pre-apheresis CD34+ count and number of interruptions during the LVL were significant factors influencing the stem cell yield (p < 0.05). Adverse drug reactions during the apheresis and post-ASCT period were manageable. Conclusion: The LVL is safe and cost-effective in attaining a minimum of CD34+ cells in a single procedure with manageable adverse reactions. Judicious intervention during the procedure may be helpful in ensuring the adequate yield.Gopal Krushna RayRabindra Kumar JenaTribikram PandaSudha SethyElsevierarticleGCSFLarge volume leukapheresis (LVL)PlerixaforStem cell yieldDiseases of the blood and blood-forming organsRC633-647.5ENHematology, Transfusion and Cell Therapy, Vol 43, Iss 4, Pp 402-409 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	GCSF Large volume leukapheresis (LVL) Plerixafor Stem cell yield Diseases of the blood and blood-forming organs RC633-647.5
spellingShingle	GCSF Large volume leukapheresis (LVL) Plerixafor Stem cell yield Diseases of the blood and blood-forming organs RC633-647.5 Gopal Krushna Ray Rabindra Kumar Jena Tribikram Panda Sudha Sethy Prospective identification of potential factors influencing stem cell mobilization and the necessity for plerixafor use in newly diagnosed multiple myeloma patients undergoing autologous stem cell transplantation
description	Introduction: To study the efficacy and safety of single large volume leukapheresis by using generic G-CSF or G-CSF plus Plerixafor in achieving adequate stem cell yield and various factors influencing thereof in newly diagnosed multiple myeloma patients undergoing autologous stem cell transplant . Method: This prospective study was undertaken among 55 newly diagnosed multiple myeloma patients undergoing autologous stem cell transplant and aged between 18 and 75 years. Mobilization and harvesting of stem cells were performed by using GCSF or GCSF plus Plerixafor and large volume leukapheresis, respectively. A stem cell yield of ≥2 × 106 kg–1 and the number of apheresis procedures were primary efficacy endpoints, while the ideal stem cells yield >5 × 106 kg–1, the engraftment day and D100 response/graft sustainability were secondary endpoints. Result: The primary endpoint was achieved in all cases in both the groups by using a single LVL leukapheresis procedure. Fulfillment of all the secondary endpoints was satisfactory and comparable in both the groups. Age, pre-apheresis CD34+ count and number of interruptions during the LVL were significant factors influencing the stem cell yield (p < 0.05). Adverse drug reactions during the apheresis and post-ASCT period were manageable. Conclusion: The LVL is safe and cost-effective in attaining a minimum of CD34+ cells in a single procedure with manageable adverse reactions. Judicious intervention during the procedure may be helpful in ensuring the adequate yield.
format	article
author	Gopal Krushna Ray Rabindra Kumar Jena Tribikram Panda Sudha Sethy
author_facet	Gopal Krushna Ray Rabindra Kumar Jena Tribikram Panda Sudha Sethy
author_sort	Gopal Krushna Ray
title	Prospective identification of potential factors influencing stem cell mobilization and the necessity for plerixafor use in newly diagnosed multiple myeloma patients undergoing autologous stem cell transplantation
title_short	Prospective identification of potential factors influencing stem cell mobilization and the necessity for plerixafor use in newly diagnosed multiple myeloma patients undergoing autologous stem cell transplantation
title_full	Prospective identification of potential factors influencing stem cell mobilization and the necessity for plerixafor use in newly diagnosed multiple myeloma patients undergoing autologous stem cell transplantation
title_fullStr	Prospective identification of potential factors influencing stem cell mobilization and the necessity for plerixafor use in newly diagnosed multiple myeloma patients undergoing autologous stem cell transplantation
title_full_unstemmed	Prospective identification of potential factors influencing stem cell mobilization and the necessity for plerixafor use in newly diagnosed multiple myeloma patients undergoing autologous stem cell transplantation
title_sort	prospective identification of potential factors influencing stem cell mobilization and the necessity for plerixafor use in newly diagnosed multiple myeloma patients undergoing autologous stem cell transplantation
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/a95b46c4541f464eb7de7b52a9705552
work_keys_str_mv	AT gopalkrushnaray prospectiveidentificationofpotentialfactorsinfluencingstemcellmobilizationandthenecessityforplerixaforuseinnewlydiagnosedmultiplemyelomapatientsundergoingautologousstemcelltransplantation AT rabindrakumarjena prospectiveidentificationofpotentialfactorsinfluencingstemcellmobilizationandthenecessityforplerixaforuseinnewlydiagnosedmultiplemyelomapatientsundergoingautologousstemcelltransplantation AT tribikrampanda prospectiveidentificationofpotentialfactorsinfluencingstemcellmobilizationandthenecessityforplerixaforuseinnewlydiagnosedmultiplemyelomapatientsundergoingautologousstemcelltransplantation AT sudhasethy prospectiveidentificationofpotentialfactorsinfluencingstemcellmobilizationandthenecessityforplerixaforuseinnewlydiagnosedmultiplemyelomapatientsundergoingautologousstemcelltransplantation
_version_	1718445292160811008

Prospective identification of potential factors influencing stem cell mobilization and the necessity for plerixafor use in newly diagnosed multiple myeloma patients undergoing autologous stem cell transplantation

Ejemplares similares